Symbicort in steroid-dependent asthma: reduction of oral steroids requirements
https://doi.org/10.18093/0869-0189-2005-0-4-71-79
Abstract
Objective: to study the ability of inhaled Symbicort to reduce daily oral steroids (OS) requirements in patients with severe steroid-dependent asthma.
Methods: 16 patients with severe steroid-dependent asthma were included into the study (5 males, 11 females, mean age 53 ± 8 years, mean dose of OS 10.9 ± 5.2 mg / day, mean OS treatment duration 9.3 ± 4.1 years, mean FEV1 59.3 ± 15.1%). All patients received Symbicort administered by means of a multidose poder inhaler 4.5 / 160 mkg 2 inhalations twice daily, every 2 weeks patients underwent controlled OS reduction on the basis of predetermined asthma stability criteria.
Results: OS was eliminated or reduced in 14 patients (87.5 %), the OS dose was reduced to 3.3 ± 6.8 mg / day (р < 0.001). At the end of 12 weeks of Symbicort therapy FEV1 and FVC increased by 18.6 % and 8.9 %, respectively. Daytime and nighttime asthma symptom severity scores improved in average by 1 point (р < 0.001). The number of inhalations of short-acting β2-agonists reduced from 3.4 ± 1.7 to 1.5 ± 1.3 puffs / day (р < 0.001). Statistically and clinically significant improvements were seen in all 4 domains of quality of life scores (AQLQ) (р < 0.001). The level of NOex reduced significantly form 18.6 ± 11.4 ppb at baseline to 7.9 ± 2.8 ppb after 12 weeks (р = 0.001). The side effects of OS were reduced to the end of study.
Conclusion: in patients with severe steroid-dependent asthma therapy with Symbicort allows to eliminate or reduce OS therapy with improved lung function, improved daytime and nighttime asthma symptoms, improved asthma-specific quality of life, reduction of short-acting β2-agonists use and reduction of side effects of OS.
About the Authors
S. N. Avdeev
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
Z. S. Etteeva
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
N. A. Voznesensky
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
N. N. Mesheriakova
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
A. G. Chuchalin
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
References
1. Global strategy for asthma management and prevention NHLBI / WHO Workshop Report: NIH Publication No 02-3659. The 2002 report updated in 2004 is available on www.ginasthma.com.
2. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled cortico-steroids. New developments. Am. J. Respir. Crit. Care Med. 1998; 157: S1–S53.
3. NAEPP (National Asthma Education and Prevention Program) Expert Panel. NAEPP expert panel report: Guidelines for the diagnosis and management of asthma — update on selected topics 2002. Bethesda, Md.: National Institutes of Health, July 2002a. NIH Publication №. 025075.
4. British Thoracic Society and Scottish Intercollegiate Guidelines Network Guidelines on Asthma. Thorax 2003; 58 (suppl. I): i1-i94.
5. Lemiere C., Bai T., Balter M. et al, on behalf of the Canadian Adult Consensus Group of the Canadian Thoracic Society. Adult asthma consensus guidelines update 2003. Can. Respir. J. 2004; 11(Suppl. A): 9A–18A.
6. Leone F.T., Grana J.R., McDermott P., et al. Pharmaceutically-based severity stratification of an asthmatic population. Respir. Med. 1999; 93: 788–793.
7. Wenzel S. Severe asthma in adults. Am. J. Respir. Crit. Care Med. 2005; 172: 149–160.
8. Niven A.S., Argyros G. Alternate treatments in asthma. Chest 2003; 123:1254–1265.
9. Davies H., Olson L., Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst. Rev. 2000; Issue 2: CD000391.
10. Evans D.J., Cullian P., Geddes D.M. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst. Rev. 2001; Issue 2: CD002993.
11. Evans D.J., Cullian P., Geddes D.M. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst. Rev. 2001; Issue 2: CD002985.
12. Landwehr L.P., Jeppson J.D., Katlan M.G., et al. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 1998; 114: 1349-1356.
13. Dewey A., Dean T., Bara A. et al. Colchicine as an oral corticosteroid sparing agent for asthma. Cochrane Database of Syst. Rev. 2003, Issue 3: CD003273.
14. Dewey A., Bara A., Dean T., Walters H. Dapsone as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst. Rev. 2002; Issue 4: CD003268.
15. Noonan M., Chervinsky P., Busse W.W, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am. J. Respir. Crit. Care Med. 1995; 152: 1467–1473.
16. Nelson H.S., Bernstein I.L., Fink J. et al. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort Turbuhaler Study Group. Chest 1998; 113: 1264–1271.
17. Nelson H.S., Busse W.W., deBoisblanc B.P. et al. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J. Allergy Clin. Immunol. 1999; 103: 267–275.
18. Fish J.E., Karpel J.P., Craig T.J. et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J. Allergy Clin. Immunol. 2000; 106: 852–860.
19. Pauwels R.A., Lofdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405–1411.
20. Shrewsbury S., Pyke S., Britton M. Meta-analysis of increased dose of inhaled steroid or addiction of salmeterol in symptomatic asthma (MIASMA). Br. Med. J. 2000; 320: 1368–1373.
21. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur. Respir. J. 2002; 19: 182–191.
22. Borg G. Psychophysical bases of perceived exertion. Med. Sci. Sports Exerc. 1982; 14: 377–381.
23. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J.1993; 6 (suppl. 16): 5–40.
24. American Thoracic Society. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. Am J. Respir. Crit. Care Med. 1999; 160: 2104–2117.
25. Авдеев С.Н., Анаев Э.Х., Чучалин А.Г. Применение метода индуцированной мокроты для оценки интенсивности воспаления дыхательных путей. Пульмонология 1998; 2: 81–87.
26. Juniper E.F., Guyatt G.H., Epstein R.S. et al. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76–83.
27. Суточникова О.А., Самсонова М.B., Черняк А.В. и др. Влияние отечественного ингаляционного глюкокортикостероида будесонида на воспаление и гиперреактивность бронхов при длительном лечении бронхиальной астмы. Тер. арх. 1996; 68(3): 48–50.
28. Bateman E.D., Bousquet J., Braunstein G.L. Is overall asthma control being achieved? A hypothesis-generating study. Eur. Respir. J. 2001; 17: 589–595.
29. Jones P.W. Interpretation of health status measurements: from clinical trials to routine practice. Eur. Respir. Rev. 2002; 12: 83, 87–91.
30. Juniper E.F., Guyatt G.H., Ferrie P.J., Griffith L.E. Measuring quality of life in asthma. Am. Rev. Respir. Dis. 1993; 147: 832–838.
31. Алексеева Я.Г., Лещенко И.В., Трофимов В.И., и др. Влияние терапии на качество жизни у взрослых пациентов с бронхиальной астмой. В кн.: Чучалин А.Г.: Качество жизни у больных с бронхиальной астмой, хронической обструктивной болезнью легких. Ред М., Атмосфера; 2004: 129-153.
32. Green R.H., Brightling C.E., McKenna S. et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–1721.
33. Smith A.D., Cowan J.O., Brassett K.P. et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N. Engl. J. Med. 2005; 352: 2163–2173.
34. Higgenbottam T.W., Clark R.A., Luksza A.R. et al. The role of nebulised budesonide in permitting a reduction in the dose of oral steroid in persistent severe asthma. Eur. J. Clin. Res. 1994; 5: 1–10.
Review
For citations:
Avdeev S.N., Etteeva Z.S., Voznesensky N.A., Mesheriakova N.N., Chuchalin A.G. Symbicort in steroid-dependent asthma: reduction of oral steroids requirements. PULMONOLOGIYA. 2005;(4):71-79. (In Russ.) https://doi.org/10.18093/0869-0189-2005-0-4-71-79
Views:
316
Email this article 